tbuckley/cabot-search huggingface dataset:
Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease
Authors: Bertil Lindahl, Tomasz Baron, David Erlinge, Nermin Hadziosmanovic, Anna Nordenskjöld, Anton Gard, Tomas Jernberg
Journal: Circulation (2017)

Background: Myocardial infarction with nonobstructive coronary arteries (MINOCA) occurs in 5% to 10% of all patients with myocardial infarction. Clinical trials of secondary prevention treatment in MINOCA patients are lacking. Therefore, the aim of this study was to examine the associations between treatment with statins, renin-angiotensin system blockers, β-blockers, dual antiplatelet therapy, and long-term cardiovascular events. Methods: This is an observational study of MINOCA patients recorded in the SWEDEHEART registry (the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapy) between July 2003 and June 2013 and followed until December 2013 for outcome events in the Swedish Cause of Death Register and National Patient Register. Of 199 162 myocardial infarction admissions, 9466 consecutive unique patients with MINOCA were identified. Among those, the 9136 patients surviving the first 30 days after discharge constituted the study population. Mean age was 65.3 years, and 61% were women. No patient was lost to follow-up. A stratified propensity score analysis was performed to match treated and untreated groups. The association between treatment and outcome was estimated by comparing between treated and untreated groups by using Cox proportional hazards models. The exposures were treatment at discharge with statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and dual antiplatelet therapy. The primary end point was major adverse cardiac events defined as all-cause mortality, hospitalization for myocardial infarction, ischemic stroke, and heart failure. Results: At discharge, 84.5%, 64.1%, 83.4%, and 66.4% of the patients were on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and dual antiplatelet therapy, respectively. During the follow-up of a mean of 4.1 years, 2183 (23.9%) patients experienced a major adverse cardiac event. The hazard ratios (95% confidence intervals) for major adverse cardiac events were 0.77 (0.68–0.87), 0.82 (0.73–0.93), and 0.86 (0.74–1.01) in patients on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and β-blockers, respectively. For patients on dual antiplatelet therapy followed for 1 year, the hazard ratio was 0.90 (0.74–1.08). Conclusions: The results indicate long-term beneficial effects of treatment with statins and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on outcome in patients with MINOCA, a trend toward a positive effect of β-blocker treatment, and a neutral effect of dual antiplatelet therapy. Properly powered randomized clinical trials to confirm these results are warranted.
Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities.
Authors: Deirdra R. Terrell, Jedidiah J. Perdue, Johanna Kremer-Hovinga, Bernhard Lammle, James N. George, Sara K. Vesely
Journal: Blood (2004)
Variations in Occurrence of Pathologic Calcification, Nephritis, and Amyloidosis in Mice Fed Control and Modified Diets
Authors: Walter E. Heston, C. Donald Larsen, Margaret K. Deringer
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Variations in Occurrence of Pathologic Calcification, Nephritis, and Amyloidosis in Mice Fed Control and Modified Diets Get access Walter E. Heston, Walter E. Heston Search for other works by this author on: Oxford Academic PubMed Google Scholar C. Donald Larsen, C. Donald Larsen Search for other works by this author on: Oxford Academic PubMed Google Scholar Margaret K. Deringer Margaret K. Deringer Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 1, August 1945, Pages 41–47, https://doi.org/10.1093/jnci/6.1.41 Published: 01 August 1945
Evaluation of Risk Factors for Infections and Systemic Reactions (SRs) Associated with Subcutaneous and Sublingual Allergen Immunotherapy (SCIT and SLIT): AAAAI/ACAAI National Surveillance Study 2008-2015
Authors: Tolly Epstein, Gary M. Liss, Karen J. Murphy-Berendts, David I. Bernstein
Journal: Journal of Allergy and Clinical Immunology (2017)
Enhancing the care of cancer patients with ureteral strictures managed with percutaneous nephrostomy tubes.
Authors: Sharjeel H Sabir, Rakhi Patel, Brenda Lin, Judy Ahrar, Alda Tam, Kamran Ahrar
Journal: Journal of Clinical Oncology (2016)

e264 Background: Ureteral strictures resulting from either active disease or the sequelae of cancer therapy are often managed with percutaneous nephrostomy (PCN) tubes. PCN tubes divert urine from the kidney into drainage bags, which are cumbersome to care for and potential sources of infection. In contrast, percutaneous nephroureteral (PCNU) tubes by allowing internal drainage can preclude the need for a urine drainage bag. Our goal was to implement a coordinated care program in interventional radiology (IR) designed to increase the number of patients whose PCN tubes were converted to PCNU tubes, thus preventing the long-term problems associated with urine drainage bags. Methods: An IRB approved retrospective review of all PCN tubes placed in IR from 2011-2013 was undertaken to get baseline statistics. After review of this data, a prospective care coordination program was implemented in which patients without contraindications for conversion to PCNU tubes had an attempt at conversion during their planned 3 month PCN tube exchange. The baseline and 1 year follow up data were collected. A Fisher’s exact test was used to calculate the significance of the intervention. Results: Our baseline data demonstrated on average 9% of PCN placements per year were being converted to PCNU tubes. After implementation of the prospective care coordination program from 7/2014 to 7/2015, 257 patients had PCN tubes placed. 217 patients had completed 3 month follow up at time of analysis. Of these, 30 (14%) patients had an attempt at PCNU placement because of the prospective program. Among these patients 19/30 (63%) had a successful PCNU placement. 20 (9%) patients had PCNU placement at the request of referring physicians. Overall, 39 (18%) patients had a PCNU tube placed after implementation of the program. 2/39 patients had difficulties with their PCNU tubes requiring return to PCN tubes. Conclusions: An active coordinated care program in IR aimed at preventing the long-term problems associated with PCN tubes and urinary drainage bags can increase the percentage of patients who receive PCNU tubes from 9% to 18% (p = 0.002).
The impact of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers.
Authors: Kelly A. Metcalfe, Henry T. Lynch, Carrie L. Snyder, William Foulkes, Nadine M. Tung, Charmaine Kim-Sing, Olufunmilayo I. Olopade, Andrea Eisen, Barry Rosen, Ping Sun, Steven Narod
Journal: Journal of Clinical Oncology (2014)

1507 Background: Oophorectomy is often recommended to women with BRCA-associated breast cancer in order to prevent a second primary breast cancer and ovarian cancer. However, it is unclear if oophorectomy has an impact on survival in women with BRCA-associated breast cancer. The objective of the current study was to estimate the impact of oophorectomy on survival from breast cancer for women with a BRCA1 or BRCA2 mutation Methods: 760 women with Stage I or Stage II breast cancer and a BRCA1 or BRCA2 mutation, between the ages 25 and 65, were followed for up to 20 years from diagnosis. The impact of oophorectomy on survival was evaluated in a Cox proportional hazards model, adjusting for age, gene (BRCA1 versus BRCA2), tumour stage, ER status and other treatments. Results: Of the 760 women, 455 had an oophorectomy, either prior to or after the diagnosis of breast cancer. The 20-year survival for the entire patient cohort was 74.3%. The un-adjusted hazard ratio for death associated with oophorectomy was 0.62 (95% CI: 0.42 to 0.90; p = 0.01) and the adjusted hazard ratio was 0.66 (95% CI 0.42 – 1.02; p = 0.06). The hazard ratio was 0.59 (95% CI: 0.34 – 1.01; p = 0.05) for BRCA1 carriers and was 0.81 (95% CI: 0.35 -1.85; p = 0.61) for BRCA2 carriers. The adjusted hazard ratio was 0.77 (95% CI 47 – 1.28; p = 0.29) for women diagnosed under age 50 and was 0.38 (95% CI: 0.12 to 1.15; p = 0.09) for women diagnosed over age 50. The hazard ratio was 1.21 (95% CI: 0.55 to 2.67; p = 0.65) for women with estrogen receptor-positive breast cancer and was 0.27 (95% CI: 0.11 to 0.67; p = 0.005) for women with estrogen receptor-negative breast cancer. Conclusions: Oophorectomy is associated with a decrease in mortality in women with early-stage breast cancer and a BRCA1 mutation. Women with estrogen receptor-negative breast cancer and a BRCA1 mutation should consider oophorectomy shortly after diagnosis as part of their treatment plan.
235P Phase 1b study of nimotuzumab in combination with concurrent chemoradiotherapy in Japanese patients with locally advanced esophageal cancer
Authors: T. Ura, K. Kato, W. Koizumi, S. Iwasa, C. Katada, M. Azuma, S. Ishikura, Y. Nakao, H. Onuma, K. Muro
Journal: Annals of Oncology (2016)
293P Serum free testosterone predicts a positive prostate biopsy in patients with PSA levels of 4-10ng/ml without any clinical findings
Authors: Y. Ishizuya, T. Ujike, A. Kawashima, A. Nagahara, K. Fujita, R. Imamura, H. Kiuchi, Y. Miyagawa, M. Uemura, N. Nonomura
Journal: Annals of Oncology (2016)
OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence
Authors: John F. McCauley, Hector M. Gonzalez, David James Osborn
Journal: JAMA (2017)

To the Editor At least 3 different issues related to study design, internal validity, and external validity of the trial of onabotulinumtoxinA vs sacral neuromodulation limit the generalizability of the findings.1
Depletion of CD45RA+ Cells from Mobilized Peripheral Blood Stem Cell (PBSC) Collections As an Integral Part of Hematopoietic Stem Cell Transplantation (HSCT) and Cellular Therapy (CT)
Authors: Ping Law, Paul W. Eldridge, James Houston, Brandon M. Triplett, David R Shook, Wing Leung
Journal: Blood (2014)
Care home residents show higher incidence of venous thromboembolism
Authors: Susan Mayor
Journal: BMJ (2017)

The incidence of venous thromboembolism (VTE) is much higher in care home residents than in people living in the community, a UK prospective cohort study has found.1

The risk of VTE—which comprises deep vein thrombosis and pulmonary embolism—increases with age, immobilisation, and comorbidities such as heart failure and diabetes. The risk of VTE in patients admitted to hospital is high, so inpatients …
A targeted salvage therapy with brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients who received autologuos stem cell transplantation (ASCT).
Authors: Nurdan Tacyildiz, Emel Unal, Gulsan Yavuz, Handan Dincaslan, Gulsah Tanyildiz, Esra Pekpak
Journal: Journal of Clinical Oncology (2015)

e21002 Background: Hodgkin Lymphoma(HL) is highly curable disease when in early stages,but in advanced stages it becomes a big dilemma, when it is refractory or relapsed after several chemoterapy courses. Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin E, a microtubule-disrupting agent, by a protease-cleavable linker. It has been shown in adult studies as effective salvage therapy for relapse after ASCT or for primary refractory HL. Methods: Between July 2012-February 2015, we applied BV (1,8 mg/m2-every 3 weeks; 2- 8 courses) - AVD (Doxorubucin, Vinblastin, Dacarbazin; 2- 6 courses) combination treatment on seven pediatric HL patients that have been severaly treated for refractory or ralapsed advanced stage HL, either before ( 6 patients ) or after ( one patient) ASCT in our center . Results have been assesed according to patients clinical status, sedimantion rate, and PET results. Results: One patient who received BV after his disease relapse 9 months later his ASCT was first pediatric patient who received BV in our center and country. He was in remission with negative PET result after 4 courses BV- AVD ( Alternating, Rituximab - ICE; R-ICE, due to his CD 20 positivity in tumor tissue). After 8 courses of BV he was able to performed MUD (Match unrelated Donor) SCT, and is doing well with no severe side effect. Other 6 pediatric HL patients were not able to get remission with any other classical HL chemotherapy protocols (but only one who showed early relapse just before her ASCT ) received 2-6 courses of BV- AVD ( some of them alternate with R-ICE, due to CD 20 positivity in their tumor tisue) and all were able to receive ASCT with negative PET imaging result and with normal sedimantation rate. There was no other side effects but only mild myelosuppression. Patients are in remission after 22 days -3 years (median 9 months) of posttransplant follow up. Conclusions: BV is a well tolarated and encouraging, effective targeted therapy especially when combined with AVD or alterned with another targeted therapy combination R-ICE, when needed.
Assessment of Myocardial Microstructural Dynamics by In Vivo Diffusion Tensor Cardiac Magnetic Resonance
Authors: Sonia Nielles-Vallespin, Zohya Khalique, Pedro F. Ferreira, Ranil de Silva, Andrew D. Scott, Philip Kilner, Laura-Ann McGill, Archontis Giannakidis, Peter D. Gatehouse, Daniel Ennis, Eric Aliotta, Majid Al-Khalil, Peter Kellman, Dumitru Mazilu, Robert S. Balaban, David N. Firmin, Andrew E. Arai, Dudley J. Pennell
Journal: Journal of the American College of Cardiology (2017)

Cardiomyocytes are organized in microstructures termed sheetlets that reorientate during left ventricular thickening. Diffusion tensor cardiac magnetic resonance (DT-CMR) may enable noninvasive interrogation of in vivo cardiac microstructural dynamics. Dilated cardiomyopathy (DCM) is a condition of abnormal myocardium with unknown sheetlet function.This study sought to validate in vivo DT-CMR measures of cardiac microstructure against histology, characterize microstructural dynamics during left ventricular wall thickening, and apply the technique in hypertrophic cardiomyopathy (HCM) and DCM.In vivo DT-CMR was acquired throughout the cardiac cycle in healthy swine, followed by in situ and ex vivo DT-CMR, then validated against histology. In vivo DT-CMR was performed in 19 control subjects, 19 DCM, and 13 HCM patients.In swine, a DT-CMR index of sheetlet reorientation (E2A) changed substantially (E2A mobility ∼46°). E2A changes correlated with wall thickness changes (in vivo r2 = 0.75; in situ r2 = 0.89), were consistently observed under all experimental conditions, and accorded closely with histological analyses in both relaxed and contracted states. The potential contribution of cyclical strain effects to in vivo E2A was ∼17%. In healthy human control subjects, E2A increased from diastole (18°) to systole (65°; p < 0.001; E2A mobility = 45°). HCM patients showed significantly greater E2A in diastole than control subjects did (48°; p < 0.001) with impaired E2A mobility (23°; p < 0.001). In DCM, E2A was similar to control subjects in diastole, but systolic values were markedly lower (40°; p < 0.001) with impaired E2A mobility (20°; p < 0.001).Myocardial microstructure dynamics can be characterized by in vivo DT-CMR. Sheetlet function was abnormal in DCM with altered systolic conformation and reduced mobility, contrasting with HCM, which showed reduced mobility with altered diastolic conformation. These novel insights significantly improve understanding of contractile dysfunction at a level of noninvasive interrogation not previously available in humans.
Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan
Authors: Naoki Oishi, Tetsuo Kondo, Tadao Nakazawa, Kunio Mochizuki, Tomohiro Inoue, Kazunari Kasai, Ippei Tahara, Tomonori Yabuta, Mitsuyoshi Hirokawa, Akira Miyauchi, Ryohei Katoh
Journal: Endocrine Pathology (2017)
Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).
Authors: Shreyans A Gandhi, Victoria T Potter, Victoria J. Tindell, Rachel Kesse-Adu, Laura Reiff-Zall, Michelle Kenyon, Judith C. W. Marsh, Aloysius Y Ho, Ghulam J. Mufti, Antonio Pagliuca, ZiYi Lim
Journal: Blood (2010)
Tumor response and toxicity in neoadjuvant erlotinib in early-stage NSCLC patients.
Authors: H. M. Klomp, E. Schaake
Journal: Journal of Clinical Oncology (2011)

7030 Background: Despite radical surgery, in patients with early-stage non-small cell lung cancer (NSCLC), disease recurrence becomes apparent in ~40%. The development of “targeted therapy” has induced new options to improve outcome in selected patients. This report presents the results regarding toxicity and response to neoadjuvant erlotinib in NSCLC. Methods: This study was designed as an open-label phase II trial, performed in four hospitals in the Netherlands, according to a Simon’s minimax 2-stage procedure. Initially, operable patients with early-stage NSCLC (n=15) were entered from an “enriched” population (never-smoker, female gender, non-squamous histology or Asian ethnicity), thereafter unselected to a total of n=60. Patients received preoperative erlotinib 150 mg once daily for 3 weeks. Response to treatment was evaluated using [18F]-FDG-PET, CT and pathological examination of the resection specimen. Primary endpoints were toxicity and pathologic response. Results: Sixty patients were included. Seven patients stopped treatment prematurely (12%). Skin toxicity was present in 37 patients (62%), diarrhea in 21 patients (35%). PET evaluation revealed a metabolic response (>25% SUV decrease) in 16 patients (27%), CT evaluation using RECIST showed response in 4 (7%). Pathologic examination showed significant response in 14 patients (23%), in 3 (5%) near-complete pathologic response. Characteristics and response data of both groups are shown in the table. Conclusions: According to predefined criteria, this treatment has sufficient activity to deserve further testing in future studies in an enriched population (response 34%). Metabolic evaluation of response by [18F]-FDG-PET may reflect clinical activity of erlotinib more accurately than CT. Characteristics Total population Enriched population Unselected population N=60 N=29 N=31 Sex M/ F 26/34 3/26 22/9 Mean age 64 59 64 Pathology Large cell ca 4 1 3 Squamous cell ca 12 0 12 Adeno ca 38 26 12 Other 6 2 4 EGFR mutation 7 5 2 Kras mutation 12 6 6 Median change SUV max -10% -20% 1% Metabolic responders 16 10 6 Median T change (mm) -0.3 -1.3 0.7 RECIST responders 3 3 0 Median % necrosis 29% 40% 18%
CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia
Authors: Dongxia Xing, Alan G. Ramsay, William Decker, Dean A. Lee, Simon Robinson, Nina Shah, Simrit Parmar, Catherine M. Bollard, Chitra M Hosing, Richard Champlin, John G. Gribben, Elizabeth J Shpall
Journal: Blood (2011)
Avelumab (MSB0010718C; anti-PD-L1), in Japanese patients with advanced gastric cancer: results from phase Ib trial
Authors: Shuichi Hironaka, Kohei Shitara, Satoru Iwasa, Tomohiro Nishina, Kei Muro, Taito Esaki, Taroh Satoh, Hiroki Hara, Nozomu Machida, Anja von Heydebreck, Akiko Shimizu, Toshihiko Doi
Journal: Annals of Oncology (2016)
Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis
Authors: Annie Im, Frances T. Hakim, Filip Pirsl, Seth M. Steinberg, Lauren M. Curtis, Sandra A. Mitchell, Edward W. Cowen, Jennifer Hsu, Judy Baruffaldi, Licia Masuch, Juan C. Gea-Banacloche, David C. Halverson, Daniel H. Fowler, Ronald E. Gress, Steven Z. Pavletic
Journal: Blood (2015)
168O Right-sided versus left-sided primary tumor location in patients with KRASmut metastatic colorectal cancer (mCRC) treated with 1st-line anti-VEGF plus chemotherapy (CTx) - Data from the National Czech Registry
Authors: R. Obermannova, L. Ostřížková, K. Hejduk, L. Zdrazilova-Dubska, M. Vočka, R. Vyzula, B. Bencsikova, L. Petruzelka
Journal: Annals of Oncology (2016)
460P Phase I/II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL; TORG1424/OLCSG1402): results of the phase I part
Authors: A. Bessho, N. Nogami, T. Kubo, H. Kitajima, S. Ikeo, K. Kaira, S. Hosokawa, H. Yoshioka, S. Murakami, K. Watanabe, K. Kiura
Journal: Annals of Oncology (2016)
Interim 18f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma
Authors: Federica Gigli, Luca Nassi, Mara Negri, Laura Travaini, Sara Steffanoni, Sarah Jane Liptrott, Patrizia Mancuso, Paola Bertazzoni, Simona Bassi, Liliana Calabrese, Emilia Cocorocchio, Giovanni Martinelli
Journal: Blood (2008)
The management of patients with T1 adenocarcinoma of the low rectum: An updated decision analysis.
Authors: Calvin F. Johnston, George A. Tomlinson, Larissa K. F. Temple, Nancy N. Baxter
Journal: Journal of Clinical Oncology (2012)

645 Background: Patients with T1 adenocarcinoma of the low rectum are faced with a choice between Transanal Local Excision (TLE) and Abdonimoperineal Resection (APR). Fundamentally a tradeoff between quantity and quality of life, this problem is well-suited to decision analysis. A previous decision analysis examined this issue in 1999, but subsequent case series have reported TLE recurrence rates higher than that study considered plausible. Decision analytic techniques have also evolved by incorporating Markov modeling, which better accounts for the temporal aspects of the problem, and microsimulation, which allows for greater flexibility. Methods: We developed a Markov-type microsimulation to evaluate the decision between APR and TLE in T1 adenocarcinoma of the low rectum. We used the software package 'R' and have made all computer code freely available for full transparency. Critical parameters such as transition rates and utilities were elicited by systematic literature reviews and expert opinion. Conflicting values were resolved by weighted averaging and sensitivity analyses. Results: On average, selecting TLE over APR for T1 rectal cancer resulted in a loss of 0.53 years of life expectancy but a gain of 0.97 quality-adjusted life years; hence, TLE was considered the preferable option in the majority of patients. APR was preferred if and only if the patient was unwilling to yield 7% of his or her life expectancy to avoid a permanent stoma. This transition point shifted depending on the anticipated risk of recurrence after TLE. Sensitivity analysis indicated robustness of our findings. Conclusions: Though performing an APR for T1 adenocarcinoma of the low rectum does provide an extra six months of life expectancy, a TLE is the preferable approach for the majority of patients when quality-of-life is taken into consideration. The decision in an individual patient's case can be facilitated by tumour risk-stratification and by ascertaining the patient's willingness to yield life expectancy to avoid a permanent stoma.